Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor
- PMID: 19664071
- DOI: 10.1111/j.1742-4658.2009.07175.x
Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor
Abstract
The angiogenic process in the central nervous system (CNS) is basically regulated by typical angiogenic signaling systems such as vascular endothelial growth factor (VEGF)-VEGF receptors and angiopoietin-Tie receptors. In addition to regular endothelial-pericyte interaction, the CNS vasculature has a unique system of cell to cell communication between endothelial cells and astrocytes which is known as the blood-brain barrier. Among the pathological conditions of the CNS vascular network, stroke is a major disease in which the supply of blood is decreased. Pro-angiogenic therapy using natural VEGF-A has so far been unsuccessful, indicating the possible need for a new approach related to upstream or downstream regulators involved in the VEGF-signaling pathway, or alternate VEGF family members. By contrast, a pathological increase in the blood supply in the CNS is seen in brain tumors, in particular malignant gliomas. In phase II clinical trials, anti-VEGF therapies have been shown to suppress tumor growth and improve survival rates to some extent. However, tumor invasion and the distant metastasis of gliomas can occur following anti-angiogenic therapy. Further studies are needed to obtain safer clinical outcomes by developing new strategies with combination therapy using known anti-angiogenic drugs or by developing unique medicines specifically targeting the blood vessels in brain tumors.
Similar articles
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.J Clin Oncol. 2005 Feb 10;23(5):1011-27. doi: 10.1200/JCO.2005.06.081. Epub 2004 Dec 7. J Clin Oncol. 2005. PMID: 15585754 Review.
-
Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.Integr Cancer Ther. 2005 Dec;4(4):315-21. doi: 10.1177/1534735405282557. Integr Cancer Ther. 2005. PMID: 16282508 Review.
-
Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.Oncology. 2009;77(1):1-11. doi: 10.1159/000218165. Epub 2009 May 12. Oncology. 2009. PMID: 19439998 Review.
-
Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain.Anticancer Res. 2002 Jul-Aug;22(4):2147-51. Anticancer Res. 2002. PMID: 12174896
-
[VEGF, anti-vEGF and diseases].Bull Acad Natl Med. 2008 Feb;192(2):289-300; discussion 300-2. Bull Acad Natl Med. 2008. PMID: 18819684 Review. French.
Cited by
-
Differential Expression of Vascular Endothelial Growth Factor in the Cortex and Hippocampus upon Cerebral Hypoperfusion.In Vivo. 2020 Jan-Feb;34(1):191-197. doi: 10.21873/invivo.11761. In Vivo. 2020. PMID: 31882479 Free PMC article.
-
Protective Role of Capsaicin in Neurological Disorders: An Overview.Neurochem Res. 2022 Jun;47(6):1513-1531. doi: 10.1007/s11064-022-03549-5. Epub 2022 Feb 12. Neurochem Res. 2022. PMID: 35150419 Review.
-
Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis.Cancer Res. 2010 Sep 15;70(18):7283-93. doi: 10.1158/0008-5472.CAN-09-4125. Epub 2010 Sep 7. Cancer Res. 2010. PMID: 20823154 Free PMC article.
-
Neo-vascularization of the stroke cavity by implantation of human neural stem cells on VEGF-releasing PLGA microparticles.Biomaterials. 2012 Oct;33(30):7435-46. doi: 10.1016/j.biomaterials.2012.06.085. Epub 2012 Jul 18. Biomaterials. 2012. PMID: 22818980 Free PMC article.
-
VEGFA Isoforms as Pro-Angiogenic Therapeutics for Cerebrovascular Diseases.Biomolecules. 2023 Apr 20;13(4):702. doi: 10.3390/biom13040702. Biomolecules. 2023. PMID: 37189449 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous